Leukemia 31 (11): 2398-2406 (2017-11)

Hehlmann R.; Lauseker M.; Saussele S.; Pfirrmann M.; Krause S.; Kolb H.J.; Neubauer A.; Hossfeld D.K.; Nerl C.; Gratwohl A.; Baerlocher G.M.; Heim D.; Bruemmendorf T.H.; Fabarius A.; Haferlach C.; Schlegelberger B.; Mueller M.C.; Jeromin S.; Proetel U.; Kohlbrenner K.; Voskanyan A.; Rinaldetti S.; Seifarth W.; Spiess B.; Balleisen L.; Goebeler M.C.; Haenel M.; Ho A.; Dengler J.; Falge C.; Kanz L.; Kremers S.; Burchert A.; Kneba M.; Stegelmann F.; Koehne C.A.; Lindemann H.W.; Waller C.F.; Pfreundschuh M.; Spiekermann K.; Berdel W.E.; Mueller L.; Edinger M.; Mayer J.; Beelen D.W.; Bentz M.; Link H.; Hertenstein B.; Fuchs R.; Wernli M.; Schlegel F.; Schlag R.; de Wit M.; Truemper L.; Hebart H.; Hahn M.; Thomalla J.; Scheid C.; Schafhausen P.; Verbeek W.; Eckart M.J.; Gassmann W.; Pezzutto A.; Schenk M.; Brossart P.; Geer T.; Bildat S.; Schaefer E.; Hochhaus A.; Hasford J.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding IFN (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival 80% and 10-year relative survival 92%. Survival between IM400mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs. other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6, and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

Keywords: Antineoplastic Agents, Dose-Response Relationship, Drug, Hematopoietic Stem Cell Transplantation, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Survival Analysis, Young Adult

Type: Article

PubMed: 28804124
Official URL:
MDC Repository: